Anlotinib, a multi-targeted kinase inhibitor, not only inhibits VEGFR but also acts on other pathways like PDGFR and FGFR, reinforcing its anti-angiogenic effects in advanced ovarian cancer treatment (27). Here, PDGFRB is linked to ovarian carcinoma.